<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00174694</url>
  </required_header>
  <id_info>
    <org_study_id>HMR3647A_4023</org_study_id>
    <secondary_id>EudraCT # : 2004-001460-42</secondary_id>
    <nct_id>NCT00174694</nct_id>
  </id_info>
  <brief_title>CHOOSE : Telithromycin, Acute Bacterial Sinusitis</brief_title>
  <official_title>A Prospective, Randomized, Open-label, Active-controlled Study in Adult Subjects With Acute Bacterial Sinusitis Comparing the Clinical Efficacy of Telithromycin (KETEK®) 800 mg Once a Day for 5 Days Versus Amoxicillin-clavulanic Acid (AUGMENTIN®) 875/125 mg Twice a Day for 10 Days</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      Primary objective:&#xD;
&#xD;
        -  To demonstrate that the clinical efficacy of telithromycin (800 mg od for 5 days) is&#xD;
           non-inferior to amoxicillin-clavulanic acid (875/125 mg bid for 10 days) at the&#xD;
           test-of-cure (TOC) visit (Day 17-21) in subjects with acute bacterial sinusitis (ABS).&#xD;
&#xD;
      Secondary objective(s):&#xD;
&#xD;
        -  To assess the time to resolution of signs and symptoms between the baseline (Day 1) and&#xD;
           TOC (Day 17-21) visits,&#xD;
&#xD;
        -  To assess the rate of clinical relapse at the follow-up visit (Day 41-49),&#xD;
&#xD;
        -  To assess health economic outcome until follow-up visit (Day 41-49),&#xD;
&#xD;
        -  To assess quality of life up to the follow-up visit (Day 41-49),&#xD;
&#xD;
        -  To compare the safety of telithromycin and amoxicillin-clavulanic acid,&#xD;
&#xD;
        -  To compare the bacteriologic outcome of both treatments as observed at TOC (Day 17-21)&#xD;
           and at follow-up visit (Day 41-49),in subjects with ABS.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2004</start_date>
  <primary_completion_date type="Actual">December 2005</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>clinical success rate at the TOC visit in the per protocol population.</measure>
    <time_frame>During all the study conduct</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time of regression of signs and symptoms of sinusitis, rate of clinical relapse at follow-up visit.Bacteriological data.Safety data...</measure>
    <time_frame>During all the study conduct</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">298</enrollment>
  <condition>Sinusitis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telithromycin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Non pregnant female&#xD;
&#xD;
          -  Outpatients with a clinical diagnosis of ABS, based on the presence of:&#xD;
&#xD;
               -  Signs and symptoms lasting longer than 7 days and less than 28 days,&#xD;
&#xD;
               -  Purulent anterior or posterior nasal discharge&#xD;
&#xD;
               -  One additional major sign and symptom or 2 minor signs and symptoms. The major&#xD;
                  and minor signs and symptoms will be defined as the following:&#xD;
&#xD;
                    -  Major signs and symptoms: facial pain/pressure/tightness over the maxillary&#xD;
                       sinuses, nasal congestion/obstruction, change in the perception of smell&#xD;
                       (hypoanosmia/anosmia), fever (temperature &gt; 38° C [100.4 F] (oral)/ &gt; 38.5°&#xD;
                       C [101.2 F] (tympanic)/ &gt; 39° C [102.2 F] (rectal)),&#xD;
&#xD;
                    -  Minor signs and symptoms: headache, halitosis, dental pain, ear&#xD;
                       pressure/fullness, cough, fatigue,&#xD;
&#xD;
          -  Subjects with abnormal maxillary sinus x-rays (Waters views and additional views if&#xD;
             necessary) or limited sinus CT scans or sinus ultrasound in the previous 48 hours&#xD;
             before inclusion defined as the presence of at least 1 of the following homolateral&#xD;
             radiological criteria:&#xD;
&#xD;
               -  Presence of air/fluid level,&#xD;
&#xD;
               -  Total opacification,&#xD;
&#xD;
               -  Mucosal thickening &gt; 10 mm, Written informed consent must be obtained before&#xD;
                  enrollment in the study for all subjects.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Related to the disease :&#xD;
&#xD;
               -  History of recurrent sinusitis (more than (&gt;) 3 episodes of sinusitis requiring&#xD;
                  antibiotic therapy within the previous 12 months),&#xD;
&#xD;
               -  Chronic sinusitis (signs and symptoms lasting more than 28 days),&#xD;
&#xD;
               -  Suspicion of sinusitis requiring treatment other than oral antibiotic therapy,&#xD;
&#xD;
               -  Suspicion of concomitant odontologic infection, requiring antibiotic therapy or&#xD;
                  surgery&#xD;
&#xD;
               -  Nosocomial sinusitis (eg, hospitalization more than 48 hours or non ambulatory&#xD;
                  institutional confinement including nursing homes within 2 weeks),&#xD;
&#xD;
               -  Known major obstructive anatomic/functional lesions in nasopharynx: anatomical&#xD;
                  blockage (eg, chronic nasal polyps, severely deviated septum), cystic fibrosis,&#xD;
                  immotile cilia, sinus polyps,&#xD;
&#xD;
               -  Use of nasal, nasogastric or nasotracheal catheters,&#xD;
&#xD;
               -  Sinus puncture and/or sinus lavage in the previous 7 days,&#xD;
&#xD;
               -  Previous sinus surgery in the last 6 months,&#xD;
&#xD;
               -  Maxillary sinusitis requiring immediate surgery&#xD;
&#xD;
               -  Symptomatic allergic sinusitis and/or allergic rhinitis,&#xD;
&#xD;
               -  Exposition to environmental irritants in the workplace&#xD;
&#xD;
          -  Related to the previous/concomitant medication :&#xD;
&#xD;
               -  Previous treatment with intranasal, oral or parenteral antibiotic (more than 24&#xD;
                  hours intake) within 30 days prior enrollment,&#xD;
&#xD;
               -  Intranasal corticosteroid or short term systemic corticosteroid use within the&#xD;
                  past 10 days prior to enrollment,&#xD;
&#xD;
               -  Maintenance systemic corticosteroid therapy on inclusion (&gt;10 mg/day equivalent&#xD;
                  prednisone),&#xD;
&#xD;
               -  Subjects who are long-term users (&gt; 4 weeks) of nasal decongestants like&#xD;
                  oxymetazoline 0.05%,&#xD;
&#xD;
               -  Required on-therapy contra-indicated medications with study treatment (according&#xD;
                  to the country labeling): ergot alkaloids derivatives (such as ergotamine and&#xD;
                  dihydroergotamine), cisapride, pimozide, astemizole, terfenadine, simvastatin,&#xD;
                  atorvastatin and lovastatin, allopurinol, methotrexate, probenecid,&#xD;
&#xD;
               -  Previous treatment within 2 weeks before enrollment or during the study&#xD;
                  medication with rifampicin, phenytoin, carbamazepine, St-John's-wort,&#xD;
                  phenobarbital,&#xD;
&#xD;
               -  Treatment with any investigational product in the last 30 days before study&#xD;
                  entry.&#xD;
&#xD;
          -  Other exclusion criteria&#xD;
&#xD;
               -  Subject with mononucleosis, phenylketonuria,&#xD;
&#xD;
               -  Immunocompromised subjects, such as: subjects with known HIV subjects and those&#xD;
                  who have either had an AIDS-defining condition (eg, Kaposi's sarcoma,&#xD;
                  Pneumocystis carinii pneumonia) or have CD4+ T-lymphocyte count &lt; 200/mm3, known&#xD;
                  neutropenia (&lt; 1500 neutrophils/mm3) not attributable to the acute infectious&#xD;
                  disease, metastatic or hematological malignancy, splenectomized or known&#xD;
                  hyposplenia or asplenia,&#xD;
&#xD;
               -  History of congenital or a family history of long QT syndrome (if not excluded by&#xD;
                  previous ECG),&#xD;
&#xD;
               -  Subjects with known acquired QT interval prolongation,&#xD;
&#xD;
               -  Subjects with myasthenia gravis,&#xD;
&#xD;
               -  Subjects with galactose intolerance,&#xD;
&#xD;
               -  Subjects with a progressively fatal disease, life expectancy £ 3 months,&#xD;
&#xD;
               -  Women who are breast-feeding or are pregnant or childbearing potential (ie,&#xD;
                  ovulating, premenopausal, not surgically sterile) or who are failing to use&#xD;
                  adequate contraception for example systemic hormones (birth control pills,&#xD;
                  implant), intrauterine device or barrier method (diaphragm with intravaginal&#xD;
                  spermicide, cervical cap, male or female condom). A urine or serum test will be&#xD;
                  carry out before enrollment in the study,&#xD;
&#xD;
               -  History or known hypersensitivity and/or adverse reactions to telithromycin or&#xD;
                  macrolides, amoxycillin-clavulanic acid or betalactams,&#xD;
&#xD;
               -  Clinically relevant cardiovascular, hepatic, neurologic, endocrine, or other&#xD;
                  major systemic disease making implementation of the protocol or interpretation of&#xD;
                  the study results difficult,&#xD;
&#xD;
               -  History of drug or alcohol abuse rendering subjects unable to comply with&#xD;
                  protocol,&#xD;
&#xD;
               -  Known or history of severe impaired renal function, as shown by a previous&#xD;
                  laboratory value of creatinine clearance ≤ 30 ml/min either measured or estimated&#xD;
                  with Cockroft formula or serum creatinine &gt; or =2.0 mg/dL (&gt; or =176 μmol/L),&#xD;
&#xD;
               -  Mental condition rendering the subjects unable to understand the nature, scope,&#xD;
                  and possible consequences of the study,&#xD;
&#xD;
               -  Subjects unlikely to adhere to the protocol, eg, uncooperative attitude,&#xD;
                  inability to return for follow-up visits, and unlikelihood of completing the&#xD;
                  study,&#xD;
&#xD;
               -  Subject is the investigator or any subinvestigator, research assistant,&#xD;
                  pharmacist, study coordinator, other staff or relative thereof involved in the&#xD;
                  conduct of the protocol,&#xD;
&#xD;
               -  Subjects having already been included in this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gilles Perdriset, MD</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <removed_countries>
    <country>Canada</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Portugal</country>
    <country>Turkey</country>
  </removed_countries>
  <results_reference>
    <citation>Desrosiers M, Ferguson B, Klossek JM, Drugeon H, Mösges R. Clinical efficacy and time to symptom resolution of 5-day telithromycin versus 10-day amoxicillin-clavulanate in the treatment of acute bacterial sinusitis. Curr Med Res Opin. 2008 Jun;24(6):1691-702. doi: 10.1185/03007990802133914.</citation>
    <PMID>18559163</PMID>
  </results_reference>
  <verification_date>September 2009</verification_date>
  <study_first_submitted>September 9, 2005</study_first_submitted>
  <study_first_submitted_qc>September 9, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2005</study_first_posted>
  <last_update_submitted>September 24, 2009</last_update_submitted>
  <last_update_submitted_qc>September 24, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 25, 2009</last_update_posted>
  <responsible_party>
    <name_title>Medical Affairs Study Director</name_title>
    <organization>sanofi-aventis</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sinusitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Telithromycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

